Sun Pharma gets South Africa nod for generic semaglutide

Regulatory Product ApprovalBusiness Updates View source PDF

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.4%1-day move

₹1943.40

prior close

₹1955.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2-0.3-0.4-0.3+0.4-0.6+0.8+0.8+0.0-0.0————

Up moveDown movePending

AI summary

Sun Pharma received approval from South Africa's health regulator SAHPRA to manufacture and market generic semaglutide injection for adults with type 2 diabetes. The product will be a pre-filled multi-dose pen in two strengths for once-weekly dosing, with launch planned in coming days. South Africa is the second market after India where Sun Pharma has secured generic semaglutide approval. South Africa has a growing diabetes burden driven by urbanization and lifestyle changes.

Likely market impact

Opens a new market for Sun Pharma's generic semaglutide, expanding its international presence beyond India and supporting growth in emerging markets.